Are you Dr. Elamin?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 12 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161
Summary
- Dr. Yasir Elamin, MD is an oncologist in Houston, Texas. He is currently licensed to practice medicine in Texas and Oklahoma. He is affiliated with University of Texas M.D. Anderson Cancer Center.
Education & Training
- University of Khartoum Faculty of MedicineClass of 2005
Certifications & Licensure
- TX State Medical License 2018 - 2026
- OK State Medical License 2020 - 2021
Clinical Trials
- Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) Start of enrollment: 2020 Apr 08
- Study of Seribantumab in Adult Patients with NRG1 Gene Fusion Positive Advanced Solid Tumors Start of enrollment: 2024 Feb 28
- Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer Start of enrollment: 2020 Jun 18
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsAuthor Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do, Yu Qian, Xin Sun
Nature. 2025-03-01 - The Society of Thoracic Surgeons (STS) Clinical Practice Guideline on Surgical Management of Oligometastatic Non-small Cell Lung Cancer.Mara B Antonoff, Kyle G Mitchell, Samuel S Kim, Hai V Salfity, Svetlana Kotova
The Annals of Thoracic Surgery. 2025-03-01 - 3 citationsA Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve-Mutant Metastatic Non-Small Cell Lung...Xiuning Le, Jyoti D Patel, Elaine Shum, Christina Baik, Rachel E Sanborn
Journal of Clinical Oncology. 2025-02-01
Press Mentions
- A Powerhouse US Doctor Slain in Sudan, ‘Killed for Nothing’April 30th, 2023
- How Genes and Genetic Biomarkers Affect Lung CancerApril 21st, 2023
- Drug Yields High Response Rates for Lung Cancer Patients with Harsh MutationOctober 18th, 2017